FDA Grants Priority Review to Takeda's Zasocitinib for Plaque Psoriasis

summarizeSummary

The FDA accepted Takeda's zasocitinib NDA under Priority Review for moderate-to-severe plaque psoriasis, with a PDUFA decision expected in Q1 2027. Phase 3 data showed ~70% of patients achieved clear or almost clear skin at week 16.

check_boxKey Events · Product Development and Regulatory · TAK

• FDA Priority Review Acceptance

  The FDA accepted the NDA for zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis under Priority Review, with a PDUFA target action date in Q1 2027.

• Phase 3 Efficacy Data

  Across LATITUDE PsO 3001 and 3002, ~70% of patients achieved sPGA 0/1 at week 16 versus 11-13% on placebo; PASI 75 was 71-76% versus 12% on placebo. Strong efficacy was seen in scalp, nails, palms, and soles.

• EMA Parallel Review

  The European Medicines Agency also accepted Takeda's marketing authorization application for zasocitinib, initiating review for the same indication.

• Financial Impact

  Takeda stated the NDA filing has no significant impact on the full-year consolidated financial forecast for FY ending March 31, 2027.

auto_awesomeAnalysis · TAK · Life Sciences

A major regulatory milestone has been cleared for zasocitinib, Takeda's oral TYK2 inhibitor, with the FDA accepting the NDA under Priority Review and setting a PDUFA decision date in Q1 2027. The Phase 3 results are compelling: roughly 70% of patients achieved clear or almost clear skin at week 16, compared with 11-13% on placebo, and efficacy was strong in hard-to-treat areas like the scalp and nails. This positions zasocitinib as a potential best-in-class oral option in a large psoriasis market, though it will compete with Bristol Myers Squibb's Sotyktu. The parallel EMA acceptance signals global commercial ambitions. While Takeda notes no impact on FY2026 guidance, limiting the near-term financial effect, the long-term revenue opportunity is substantial.